Indium (111In) imciromab
In this article, we are going to analyze in detail Indium (111In) imciromab, a topic that has generated a great debate in contemporary society. Indium (111In) imciromab is a topic of great relevance, since it affects a wide spectrum of the population and has repercussions on various aspects of daily life. Throughout this article, we will explore different perspectives on Indium (111In) imciromab, with the aim of shedding light on its implications and generating deep reflection. From its origin to its possible solutions, including its short and long-term consequences, Indium (111In) imciromab is a topic that deserves to be addressed with seriousness and rigor, which is why it is vitally important to delve into its analysis.
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | cardiac myosin |
| Clinical data | |
| Trade names | Myoscint |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
_imciromab&sq=&lang=en&file=File:Engineered_monoclonal_antibodies.svg){kind=link}
Indium (111In) imciromab (trade name Myoscint) is a mouse monoclonal antibody labelled with the radioisotope Indium-111.[1] It was used for cardiac imaging, but withdrawn in 1993.[2]
See also
References
- ^ WHO Drug Information
- ^ "DiagnosticImaging.com: Centocor withdraws imaging agent applications". Archived from the original on 2012-02-26. Retrieved 2009-10-17.
_imciromab&sq=&lang=en&file=File:Inmunoglobulina.png){kind=small} | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
_imciromab&sq=&lang=en&file=File:Nuclear_Medicine.png){kind=small} | This nuclear medicine article is a stub. You can help Wikipedia by expanding it. |